Matches in Wikidata for { <http://www.wikidata.org/entity/Q91346386> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q91346386 description "2018 թվականի օգոստոսի 10-ին հրատարակված գիտական հոդված" @default.
- Q91346386 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91346386 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91346386 description "scientific article published on 10 August 2018" @default.
- Q91346386 description "wetenschappelijk artikel" @default.
- Q91346386 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91346386 name "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 name "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 type Item @default.
- Q91346386 label "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 label "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 prefLabel "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 prefLabel "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 P1433 Q91346386-72B0D93A-D74E-461C-A34E-A63C30A5B436 @default.
- Q91346386 P1476 Q91346386-BBC41CC4-98C4-4CBD-A428-AE15E022E163 @default.
- Q91346386 P2093 Q91346386-0F680015-A352-4402-AFBD-6C49D5C2119F @default.
- Q91346386 P2093 Q91346386-2334EAE8-6643-4D1E-A816-7A33BEBAFFAC @default.
- Q91346386 P2093 Q91346386-56347019-482E-481C-BB20-CC8D1D6621D7 @default.
- Q91346386 P2093 Q91346386-860A5F4D-981E-41BD-8C98-B9F5DCCC27D7 @default.
- Q91346386 P2093 Q91346386-C8256A9D-E392-4542-A85B-7E459612F503 @default.
- Q91346386 P2093 Q91346386-C838FF61-7813-4493-B2E2-6D7E989AAD1E @default.
- Q91346386 P2093 Q91346386-D1BAF23D-89F5-4DB2-BFDF-CC1A07F6CBBE @default.
- Q91346386 P2860 Q91346386-B34ACE69-BD07-48F4-A651-C3D6A7BE3DE6 @default.
- Q91346386 P304 Q91346386-B93648EC-F4E2-452C-8E80-F043EFF57617 @default.
- Q91346386 P31 Q91346386-7BE862B8-5A2C-42F9-B810-CC918FB1FC1D @default.
- Q91346386 P356 Q91346386-834BCF45-DB5E-44B3-855A-88772A96FADF @default.
- Q91346386 P433 Q91346386-4EF3B506-E017-4B8C-8A48-9F26297A4FE0 @default.
- Q91346386 P478 Q91346386-66B0A003-C9A3-4F97-922A-EF94E312FD17 @default.
- Q91346386 P50 Q91346386-30930A6D-F2C5-4409-8FA5-8080AD92B906 @default.
- Q91346386 P50 Q91346386-435C083D-F232-46EE-88BD-9280A6346F47 @default.
- Q91346386 P50 Q91346386-B3BD6ECB-0EAB-4B89-BD43-9AC368F68E03 @default.
- Q91346386 P577 Q91346386-1EBC3866-D5C3-4D3B-A9A1-A20982717478 @default.
- Q91346386 P698 Q91346386-BD81779E-BE10-4247-8760-1E2E31723738 @default.
- Q91346386 P921 Q91346386-23967C1A-FF10-4DD2-9F06-EBC764C4165D @default.
- Q91346386 P921 Q91346386-443E043B-4FAA-4895-88A8-16D41A17F85F @default.
- Q91346386 P921 Q91346386-86121155-F488-4734-A074-8FE10D1E5C4B @default.
- Q91346386 P921 Q91346386-C7985ECA-B5D6-493B-BD25-D0F42A10FAC2 @default.
- Q91346386 P356 J.JACL.2018.08.003 @default.
- Q91346386 P698 30197273 @default.
- Q91346386 P1433 Q15817174 @default.
- Q91346386 P1476 "Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study" @default.
- Q91346386 P2093 "Jan W Eriksson" @default.
- Q91346386 P2093 "Kristina Önnerhag" @default.
- Q91346386 P2093 "Linda Moris" @default.
- Q91346386 P2093 "Mattias Sundén" @default.
- Q91346386 P2093 "Per-Anders Jansson" @default.
- Q91346386 P2093 "Peter M Nilsson" @default.
- Q91346386 P2093 "Ulf Risérus" @default.
- Q91346386 P2860 Q38316076 @default.
- Q91346386 P304 "1390-1403.e4" @default.
- Q91346386 P31 Q13442814 @default.
- Q91346386 P356 "10.1016/J.JACL.2018.08.003" @default.
- Q91346386 P433 "6" @default.
- Q91346386 P478 "12" @default.
- Q91346386 P50 Q65992534 @default.
- Q91346386 P50 Q66191055 @default.
- Q91346386 P50 Q88866528 @default.
- Q91346386 P577 "2018-08-10T00:00:00Z" @default.
- Q91346386 P698 "30197273" @default.
- Q91346386 P921 Q1467339 @default.
- Q91346386 P921 Q1546498 @default.
- Q91346386 P921 Q269829 @default.
- Q91346386 P921 Q66299798 @default.